US 11318211
Dosage regimes for the administration of an anti-CD19 ADC
granted A61KA61K2039/505A61K2039/542
Quick answer
US patent 11318211 (Dosage regimes for the administration of an anti-CD19 ADC) held by ADC THERAPEUTICS SA expires Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- ADC THERAPEUTICS SA
- Grant date
- Tue May 03 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Apr 28 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 16
- CPC classes
- A61K, A61K2039/505, A61K2039/542, A61K2039/545, A61K31/519